Small interfering RNA (siRNA)-mediated knockdown of macrophage migration inhibitory factor (MIF) suppressed cyclin D1 expression and hepatocellular carcinoma cell proliferation

Oncotarget

Volumn 5, Issue 14, 2014, Pages 5570-5580

  Huang, Xiao Hui ^a   Jian, Wei Hua ^b   Wu, Zhao Feng ^a,b   Zhao, Jie ^a   Wang, Hua ^a   Li, Wen ^a   Xia, Jin Tang ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Cyclin D1; Hepatocellular carcinoma; Macrophage migration inhibitory factor; Proliferation; RNA interference

Indexed keywords

BIM PROTEIN; CASPASE 3; CYCLIN D1; MACROPHAGE MIGRATION INHIBITION FACTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; P CASPASE 3; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE; CONTROLLED STUDY; CORRELATIONAL STUDY; CYCLIN D1 GENE; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; HEPATOCELLULAR CARCINOMA CELL LINE; HEPG2 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MACROPHAGE MIGRATION INHIBITORY FACTOR GENE; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLC CELL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS REGULATION; TISSUE LEVEL; TUMOR GENE; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DEFICIENCY; DRUG SCREENING; GENETICS; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; FEMALE; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84906223063     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2141     Document Type: Article

References (35)

1. Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, Gores G, Kerlan R, Merle P, O'Neil B, Poon R, Schwartz L, Tepper J, Yao F, Haller D, Mooney M, Venook A. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2010; 28(25):3994-4005.
2. Chen L, Zhang Q, Chang W, Du Y, Zhang H, Cao G. Viral and host inflammation-related factors that can predict the prognosis of hepatocellular carcinoma. Eur J Cancer. 2012; 48(13):1977-1987.
3. Adamali H, Armstrong ME, McLaughlin AM, Cooke G, McKone E, Costello CM, Gallagher CG, Leng L, Baugh JA, Fingerle-Rowson G, Bucala RJ, McLoughlin P, Donnelly SC. Macrophage migration inhibitory factor enzymatic activity, lung inflammation, and cystic fibrosis. Am J Respir Crit Care Med. 2012; 186(2):162-169.
4. Arenberg D, Luckhardt TR, Carskadon S, Zhao L, Amin MA, Koch AE. Macrophage migration inhibitory factor promotes tumor growth in the context of lung injury and repair. Am J Respir Crit Care Med. 2010;182(8):1030-1037.
5. Wang D, Luo L, Chen W, Chen LZ, Zeng WT, Li W, Huang XH. Significance of the vascular endothelial growth factor and the macrophage migration inhibitory factor in the progression of hepatocellular carcinoma. Oncol Rep. 2014; 31(3):1199-1204.
6. Yu X, Lin SG, Huang XR, Bacher M, Leng L, Bucala R, Lan HY. Macrophage migration inhibitory factor induces MMP-9 expression in macrophages via the MEK-ERK MAP kinase pathway. J. Interferon Cytokine Res. 2007;27(2):103-109.
7. Zhong JC, Yu XY, Lin QX, Li XH, Huang XZ, Xiao DZ, Lin SG. Enhanced angiotensin converting enzyme 2 regulates the insulin/Akt signalling pathway by blockade of macrophage migration inhibitory factor expression. Br. J. Pharmacol. 2008;153(1):66-74.
8. Lauring J, Park BH, Wolff AC. The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer. J Natl Compr Canc Netw. 2013;11(6):670-678.
9. Cohen P, Frame S. The renaissance of GSK3. Nat Rev Mol Cell Biol. 2001; 2(10):769-776.
10. Harashima N, Inao T, Imamura R, Okano S, Suda T, Harada M. Roles of the PI3K/Akt pathway and autophagy in TLR3 signaling-induced apoptosis and growth arrest of human prostate cancer cells. Cancer Immunol Immunother. 2012; 61(5):667-676.
11. Tashiro E, Tsuchiya A, Imoto M. Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression. Cancer Sci. 2007; 98(5): 629-635.
12. Kim JK, Diehl JA. Nuclear cyclin D1: An oncogenic driver in human cancer. J Cell Physiol. 2009;220(2):292-296.
13. Llovet JM, Bruix J.Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 2008; 48(4):1312-1327.
14. Min L, He B, Hui L. 2011. Mitogen-activated protein kinases in hepatocellular carcinoma development. Semin Cancer Biol. 2011;21(1):10-20.
15. Rie Matsushima-Nishiwaki, Seiji Adachi, Takashi Yoshioka, Eisuke Yasuda,Yasumasa Yamagishi, Junya Matsuura, Masato Muko, Rutsu Iwamura,Takahiro Noda, Hidenori Toyoda, Yuji Kaneoka, Yukio Okano, Takashi Kumada, and Osamu Kozawa1. Suppression by Heat Shock Protein 20 of Hepatocellular Carcinoma Cell Proliferation via Inhibition of the Mitogen-Activated Protein Kinases and AKT Pathways. Journal of Cellular Biochemistry. 2011; 112(11):3430-3439.
16. Gerber MA, Garfinkel E, Hirschman SZ, Thung SN, Panagiotatos T. Immune and enzyme histochemical studies of a human hepatocellular carcinoma cell line producing hepatitis B surface antigen. J Immunol. 1981; 126(3):1085-1089.
17. Aden DP, Fogel A, Plotkin S, Damjanov I, Knowles BB. Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature. 1979; 282(5739):615-616.
18. Knowles BB, Howe CC, Aden DP. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science. 1980; 209(4455):497-499.
19. Mittelbronn M, Platten M, Zeiner P, Dombrowski Y, Frank B, Zachskorn C, Harter PN, Weller M, Wischhusen J. Macrophage migration inhibitory factor (MIF) expression in human malignant gliomas contributes to immune escape and tumour progression. Acta Neuropathol. 2011;122(3):353-365.
20. Schulz R, Marchenko ND, Holembowski L, Fingerle-Rowson G, Pesic M, Zender L, Dobbelstein M, Moll UM.Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression. J Exp Med. 2012; 209(2):275-289.
21. James D. Swant, Beatriz E. Rendon, Marc Symons, Robert A. Mitchell. Rho GTPase-dependent Signaling Is Required for Macrophage Migration Inhibitory Factor-mediated Expression of Cyclin D1. J Biol Chem. 2005; 280(24): 23066-23072.
22. Mitchell RA. Mechanisms and effectors of MIFdependent promotion of tumourigenesis. Cell Signal. 2004;16(1):13-19.
23. Schmitz KJ, Wohlschlaeger J, Lang H, Sotiropoulos GC, Malago M, Steveling K, Reis H, Cicinnati VR, Schmid KW, Baba HA. Activation of the ERK and AKT signaling pathway predictss poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol. 2008; 48(1):83-90.
24. Meyer-Siegler KL, Iczkowski KA, Leng L, Bucala R, Vera PL: Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145. prostate cancer cells. Journal of Immunology. 2006;177(12):8730-8739.
25. Hagemann T, Robinson SC, Thompson RG, Charles K, Kulbe H, Balkwill FR: Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis. Molecular cancer therapeutics. 2007; 6(7):1993-2002.
26. Sherr CJ. Cancer cell cycles. Science.1996; 274(5293): 1672-1677.
27. Shinozaki H, Ozawa S, Ando N, Tsuruta H, Terada M, Ueda M, Kitajima M. Cyclin D1 amplification as a new predictive classification for squamous cell carcinoma of the esophagus, adding gene information. Clin Cancer Res. 1996; 2(7): 1155-1161.
28. Yamamoto H, Ochiya T, Takeshita F, Toriyama-Baba H, Hirai K, Sasaki H, Sasaki H, Sakamoto H, Yoshida T, Saito I, Terada M. Enhanced skin carcinogenesis in cyclinD1-conditional transgenic mice:cyclinD1 alters keratinocyte response to calcium-induced terminal differentiation.Cancer Res. 2002; 62(6): 1641-1647.
29. Bernhagen J, Krohn R, Lue H, Gregory JL, Zernecke A, Koenen RR, Dewor M, Georgiev I, Schober A, Leng L, Kooistra T, Fingerle-Rowson G, Ghezzi P, Kleemann R, McColl SR, Bucala R, Hickey MJ, Weber C. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med. 2007;13(5):587-596.
30. Shi X, Leng L, Wang T, Wang W, Du X, Li J, McDonald C, Chen Z, Murphy JW, Lolis E, Noble P, Knudson W, Bucala R.CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity. 2006; 25(4):595-606.
31. Leng L, Metz CN, Fang Y, Xu J, Donnelly S, Baugh J, Delohery T, Chen Y, Mitchell RA, Bucala R. MIF signal transduction initiated by binding to CD74. J Exp Med. 2003; 197(11):1467-1476.
32. Walter A, Etienne-Selloum N, Brasse D, Khallouf H, Bronner C, Rio MC, Beretz A, Schini-Kerth VB. (2010) Intake of grape-derived polyphenols reduces C26 tumor growth by inhibiting angiogenesis and inducing apoptosis. Faseb J. 2010; 24: 3360-3369.
33. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100(1): 57-70.
34. Mehmeti I, Lenzen S, Lortz S.Modulation of Bcl-2-related protein expression in pancreatic beta cells by pro-inflammatory cytokines and its dependence on the antioxidative defense status. Mol Cell Endocrinol 2011; 332(1-2):88-96.
35. Mei-Yi Wu, Junjiang Fu, Jianming Xu, Bert W O'Malley, Ray-Chang Wu. Steroid receptor coactivator 3 regulates autophagy in breast cancer cells through macrophage migration inhibitory factor .Cell Res. 2012; 22(6): 1003-1021.